Related Experiment Videos
Effect of risperidone on prolactinoma--a case report.
Pharmacopsychiatry
|January 30, 2004
Summary
Risperidone may contribute to prolactinoma growth, as seen in a bipolar disorder patient. Bromocriptine resolved symptoms, suggesting its efficacy in managing drug-induced prolactinoma.
Area of Science:
- Endocrinology
- Neuropsychopharmacology
Background:
- Hyperprolactinemia and galactorrhea are known side effects of risperidone.
- The direct link between risperidone and prolactinoma growth remains inconclusive due to rare occurrences.
Observation:
- A patient with bipolar disorder developed a prolactinoma during risperidone treatment.
- Discontinuation of risperidone led to prolactinoma disappearance, but hyperprolactinemia and galactorrhea persisted.
Findings:
- Switching to olanzapine did not significantly alter prolactin levels or galactorrhea.
- Adding bromocriptine effectively normalized serum prolactin levels and resolved galactorrhea.
Implications:
- This case highlights a potential association between risperidone and prolactinoma development.
- Further research is warranted to elucidate the relationship between risperidone and prolactinoma growth.
- Bromocriptine appears effective in managing risperidone-induced hyperprolactinemia and associated symptoms.